NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee
Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 27 April 2017 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Shareholders are entitled to have a matter addressed by the Annual General Meeting as long as their request has been received by the Board of Directors by 10 March 2017. The Board of Directors can be contacted by email at: email@example.com, or by post at: NeuroVive Pharmaceutical AB, FAO: Greg Batcheller, Medicon Village, 223 81 Lund, Sweden.
The AGM on 28 April 2016 resolved that NeuroVive shall have a Nomination Committee comprising one member for each of the three largest shareholders in terms of voting rights based on ownership statistics maintained by Euroclear Sweden AB as of 30 September 2016. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights. The Nomination Committee’s period of office runs until a new Nomination Committee has been appointed.
The Nomination Committee for the 2017 AGM comprises:
- Anders Ermén, Chairman – nominated by Baulos Capital Belgium SA / Fredrik Olsson
- Michael Vickers – nominated by Maas Biolab LLC / Marcus Keep
- Andreas Inghammar – nominated by Eskil Elmer
In total, the Nomination Committee represents some 19 % of the votes in NeuroVive as of 30 September 2016.
The Nomination Committee’s task ahead of the AGM 2017 is to prepare proposals on the following matters to present to the AGM for resolution:
- Propose the Chairman of the AGM
- Propose the number of Board members
- Propose remuneration to Board members and remuneration to Committee members
- Propose remuneration to the Auditors
- Propose the Chairman of the Board and other Board members
- Propose guidelines for appointing members of the Nomination Committee and the assignments of the Nomination Committee
- Propose remuneration to the members of the Nomination Committee
Shareholders wishing to make proposals on the above matters can contact the Committee by email at: firstname.lastname@example.org, or by post at: NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81 Lund, Sweden. In order for the Nomination Committee to consider the proposals received with due care, proposals should be received by the Nomination Committee by no later than 1 February 2017.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, drug development and production expertise, as well as commercial partners.
NeuroVive has a project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or email@example.com
Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or firstname.lastname@example.org
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on October 26, 2016.